Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 44 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2004Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicityColler, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T.
2003Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.Sallustio, B.; Davies, B.; Coller, J.; James, H.; Gillis, D.; Somogyi, A.
2010The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivationHelsby, N.; Hui, C.; Goldthorpe, M.; Coller, J.; Soh, M.; Gow, P.; de Zoysa, J.; Tingle, M.
2009Role of active metabolites in the use of opioidsColler, J.; Christrup, L.; Somogyi, A.
2007Pharmacogenetics of opioidsSomogyi, A.; Barratt, D.; Coller, J.
2007Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemiaInglis, S.; Herbert, M.; Davies, B.; Coller, J.; James, H.; Horowitz, J.; Morris, R.; Milne, R.; Somogyi, A.; Sallustio, B.
2007CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomesDavies, B.; Coller, J.; Somogyi, A.; Milne, R.; Sallustio, B.
2007Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadonColler, J.; Joergensen, C.; Foster, D.; James, H.; Gillis, D.; Christrup, L.; Somogyi, A.
2012Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patientsColler, J.; Michalakas, J.; James, H.; Farquharson, A.; Colvill, J.; White, J.; Somogyi, A.
2012ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogeneticsBarratt, D.; Coller, J.; Hallinan, R.; Byrne, A.; White, J.; Foster, D.; Somogyi, A.